Sentences with phrase «foreign aid program»

That special tariff classification was in no way altered by recent changes to the General Preferential Tariff foreign aid program.»

Foreign Policy — Discover the actions of our government beyond our borders and the attitudes about foreign policy held by our political leaders, including the Trans - Pacific Partnership, foreign aid programs, military intervention and more.

As the crusade against communism waned, foreign aid programs had to find new reasons for existing, which is not easy.

For 50 years, foreign aid programs have been a standard feature of Western dealings with non-Western places, guided by seldom - questioned notions of assisting «modernization»...

Americans have grown cynical about foreign aid programs.

At a time of possible budget cuts to foreign aid in the US, it is important to have independent evaluations that assess the likely impacts of foreign aid programs.

To find out exactly what happens when Wakanda's foreign aid programs begin, we'll have to wait for further installments of the Marvel Cinematic Universe; maybe even a Black Panther sequel.

«Fossil fuels have been one of the greatest anti-poverty programs in history, improving the human condition more than all of the trillions of dollars of government welfare programs and foreign aid programs combined.

Not exact matches

The investment in military hardware in Trump's budget would come at an expense of foreign aid and democracy promotion programs that have been a hallmark of U.S. foreign policy for decades.

Trump's budget is already facing stiff criticism on Capitol Hill, where his desire to target foreign aid and to defund some clean water programs is drawing opposition from even some Republicans.

The February federal budget deal, meanwhile, hikes outlays in both of the two categories of «discretionary» spending, defense and federal programs from foreign aid to housing subsidies, by an unprecedented 12 %, or $ 150 billion a year in 2018 and 2019.

President Donald Trump will propose beefing up military spending and slashing domestic programs and foreign aid in his fiscal year 2018 budget to be released on Thursday.

President Donald Trump's plan to impose sharp cuts to foreign aid and domestic programs is running into opposition in Congress — and that's just from his Republican allies.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

-- Member of Parliament David Yurdiga «The federal government thinks that it is acceptable to run a $ 30 billion deficit and spending billions on foreign aid and international climate change projects, as well as on newcomer settlement programs all the while cutting over $ 100 million from the three northern territories over the course of the next five years.

A most particular threat to the human rights project is the coercive use of foreign aid and other international programs in order to advance alleged rights related to procreation, population control, and the independence of children from their parents (in the name of «children's rights»).

From church charities to foreign aid, assistance programs became acceptable only when the self - interest on all sides was clear.

Unfortunately, the food aid and development assistance budgets and programs are developed separately, and as a result the U.S. foreign assistance system is not set up to encourage a comprehensive development approach.

They are also calling for the establishment of a multi-year state aid to local road, bridge and culvert program funded by a portion of the foreign bank settlement funds or from other available sources.

After leaving the Foreign Service in 1994, Cowal worked with the U.N.'s HIV / AIDS program as director of external relations.

She described the case of Peter Piot, executive director of the U.N.'s HIV / AIDS program, where Cowal worked after leaving the U.S. Foreign Service.

Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports.

In order to project the impact of proposed cutbacks to U.S. - funded programs in South Africa, which has the greatest prevalence of HIV infection of any country, and the west African nation of Côte d'Ivoire, which has a different kind of epidemic and a different level of foreign aid dependency, the researchers used a widely - published mathematical model along with epidemiologic and cost data from each country to project the outcomes of potential programmatic responses.

Waxman Markey includes a program that would calls for U.S. aid to foreign nations to build cleaner burning stoves and set standards for them.

[BOX 3: Grants and Contracts] Financial Statements, 1957 - 1959 Financial Reports, 1957 - 1959 Financial Statements, 1958 Financial Reports 1960-1961 1962 1963 1964-1965 1966-1967 Report on Review of Source Data Preparation for Accounting Purposes, Oct. 1961 AAAS Budgets, 1968 - 1969 Financial Reports, 1968 - 1969 Financial Statements and Accountant's Opinion, 1969 Financial Statements and Accountant's Opinion, 1970 Financial Reports, 1970 - 1971 Financial Reports, 1972 Financial Reports from Operations, 1979 Budget Proposal for Fiscal Year 1974 and Projections to 1963 Report for Examination of Financial Statements and Additional Information, 1983 - 1984 Closed out Funds and Stocks AAAS Grants Committee, 1955 AID Audit - Mexico City, 1974 Asia Foundation, 1955 - 1975 Boston Concerts Carnegie Corp. - Grant to AAAS for Science Teaching Improvement Program Graham Chedd - Contract [3 folders], 1973 - 1977 DOS - AID Irene Tinker, 1973 - 1977 RISM Research for the Study of Man, 1973 - 1977 Smithsonian, 1971 - 1977 Audit, 1973 - 1977 Close Out, 1976 - 1978 GE Grant - Regional Consultants on Science Teaching, 1956 Gordon Marshall, Exhibits Contract, 1952 National Endowment of the Arts, 1973 NSF Grant - Soviet Science, 1952 Training Talented Students, 1955 Travelling High School Library, 1956 Gordon Conference on Teacher Education, 1956 Junior Academies Workshop, 1957 Proposal to NSF for Development of Science Teaching Materials for Elementary and Junior High Schools, 1961 Progress Report to the NSF on the Holiday Science Lecture Program, 1963 Proposal to the NSF for 1964 Visiting Foreign Staff Project, 1963 NSF - US - Japan Comparative Science Program, 1963 NSF - US - Japan Cooperative Science Program, 1964 WGBH, 1972 Willis Shapley, Contract Agreement, Oct. 1978 DHEW - Barrier Free Meetings, Oct. 1977 CBS News - Conquest Program Series, 1959 MISCO Contract - original, 1972 Basic Books Publishing - New Roads to Yesterday, 1963 - 1966

The White House has not said exactly how it would reduce nondefense spending by $ 54 billion to the targeted $ 461 billion, but has promised to slash foreign aid, the Environmental Protection Agency, and programs that address climate change.

At this conference, the U.S. DoD was represented by both the DoD HIV / AIDS Prevention Program (DHAPP), which is the DoD Executive Agent for HIV Prevention in foreign militaries, and the Military HIV Research Program (MHRP), which is centered at Walter Reed Army Institute of Research.

MARAD aid in development, promotion, and operation of the U.S. Merchant Marine; bilateral maritime agreements; subsidy programs; ship construction in U.S. and foreign shipyards; War Risk Insurance Program; use of ships for defense needs; sales to aliens and transfers to foreign registry of ships; U.S. Merchant Marine Academy.

In simple terms, your school has to give credit for the study abroad program, and the foreign college where you will be studying abroad must be eligible for financial aid.

You can use 529 plan funds to pay for study abroad expenses if the study program at the foreign institution is eligible for credit at the student's US home institution, and if the foreign institution is eligible for Title IV federal student aid, which can be determined by looking for the federal school code.

Socio (s): IFAD, ILO, CGAP, Asian Development Bank, Agence Française de Developpement, UK Department for International Development, Australian Government Overseas Aid Program, Ministry of Foreign Affairs of Finland, Ford Foundation, Government of Canada, Ministerio de Asuntos Exteriores y de Cooperacion, Agencia Espanola de Cooperacion Internacional para el Desarrollo, Deutsche Gesellschaft für Technische Zusammenarbeit, Michael and Susan Dell Foundation, European Commission, European Investment Bank, European Bank for Reconstruction and Development, Ministère des Affaires Etrangères et Européennes de la République Francaise, Bill and Melinda Gates Foundation, Federal Ministry for Economic Cooperation and Development of Germany, Inter-American Development Bank, Japan, Italian Republic, The Netherlands, NORAD, Swiss Confederation, Swedish International Development Cooperation Agency, United States Agency for International Development, KfW Bankengruppe, FMO Finance for Development, Omidyar Network

A higher percent of any dividend should be allocated to people with lower income, with potentially some of the money going to an energy retrofit program, climate fund (3), and / or foreign climate aid.

Climate Security Index holds that climate change will change the nature of US foreign aid and humanitarian relief, anticipation of natural and manmade disasters, and military operations, placing a new importance on developing more effective and adaptive foreign assistance programs and increasing the flexibility of US armed forces.

October 3, 2014 — «The authorities of Canada have pledged 9.76 million Canadian dollars ($ 8.6 million) to Ukraine within the Quality and Accessible Legal Aid program, Canada's Department of Foreign Affairs, Trade and Development stated.